期刊
INTERNATIONAL JOURNAL OF DRUG POLICY
卷 26, 期 10, 页码 950-957出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.drugpo.2015.07.010
关键词
People who inject drugs; Hepatitis C virus; Population estimation; Modelling
资金
- NHMRC [1035149, 1035383, 1028432, 1041742]
- Australian Government
- Australian Government Department of Health and Ageing
- MRC [MC_U105260556, G1000021, MR/K023233/1] Funding Source: UKRI
- Medical Research Council [MR/K023233/1, MC_U105260556, G1000021] Funding Source: researchfish
- National Institute for Health Research [RP-DG-0610-10055] Funding Source: researchfish
There is considerable interest in determining the impact that increased uptake of treatment for hepatitis C virus (HCV) infection will have on the burden of HCV among people who inject drugs (PWID). An understanding of the size of the population of PWID, rates of injecting cessation and HCV prevalence and incidence within the PWID population is essential for such exercises. However, these parameters are often uncertain. In this paper we review methods for estimating the size of the population of PWID and related parameters, taking into account the uncertainty that exists around data on the natural history of injecting drug use; consider issues in the estimation of HCV prevalence among PWID; and consider the importance of opioid substitution therapy and prisons as settings for the prevention and treatment of HCV infection among PWID. These latter two points are illustrated through examples of ongoing work in England, Scotland and Australia. We conclude that an improved understanding of the size of PWID populations, including current and former PWID and parameters related to injecting drug use and settings where PWID may be reached, is necessary to inform HCV prevention and treatment strategies. (C) 2015 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据